Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
Conditions
Brief summary
The immunogenicity of anti-tumor necrosis factor alpha (anti-TNF) therapy in inflammatory bowel disease (IBD) is an important cause of loss of response to therapy that may lead to escalation of dose or discontinuation of therapy. Antibodies may develop to infliximab (ATI) or to adalimumab (ATA) and cause this loss of response, also known as a secondary loss of response. An alternative approach is the addition of immunomodulator (IM) therapy to counteract the antibody response and regain efficacy of the biologic medication. The investigators' goal is to treat patients' who have lost response to adalimumab or infliximab with an immunomodulator with the goal of eliminating the circulating antibodies to the anti-TNF and restoring efficacy.
Detailed description
The immunogenicity of anti-tumor necrosis factor alpha (anti-TNF) therapy in inflammatory bowel disease (IBD) is an important cause of loss of response to therapy that may lead to escalation of dose or discontinuation of therapy. Antibodies may develop to infliximab (ATI) or to adalimumab (ATA) and cause this loss of response, also known as a secondary loss of response. In an attempt to overcome these antibodies, dose escalation can be accomplished either by increasing the dose or shortening the interval between doses. The ability of dose escalation to overcome loss of response due to the presence of ATI or ATA remains controversial. Escalation of dose increases the cost of therapy substantially. If the decision is made to discontinue therapy after a secondary loss of response, a clinician may choose to switch to an alternate anti-TNF therapy of which there are currently only four. Loss of response to one agent predicts a lesser response to other anti-TNF agents and with a limited number of therapeutic options the goal should be to optimize therapy rather than to discontinue therapy. An alternative approach is the addition of immunomodulator (IM) therapy to counteract the antibody response and regain efficacy of the biologic medication. Three such IMs known to be effective in the treatment of IBD are azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX). The SONIC trial showed that patients on infliximab and azathioprine only developed antibodies at 4% of the time as opposed to those on infliximab monotherapy who formed ATI at 13%. The same principal was shown during the COMMIT trial in which patients on infliximab alone had ATI at a rate of 20% versus 4% on methotrexate plus infliximab. Ben-Horin et al. reported five patients treated initially with infliximab monotherapy whom had secondary loss of response based on clinical symptoms. These patients had ATI and all had undetectable troughs of infliximab. In all five patients ATI became undetectable, an adequate trough level was restored and the patients regained clinical response with the addition of an immunomodulator. Combination therapy with azathioprine and infliximab has led to a higher percentage of patients in steroid free remission than either drug alone. Our goal is to treat patients' who have lost response to adalimumab or infliximab with an immunomodulator with the goal of eliminating the circulating antibodies to the anti-TNF and restoring efficacy.
Interventions
DRUGAzathioprine
Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
DRUG6 mercaptopurine
Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
DRUGMethotrexate
Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.
Sponsors
Indiana University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with inflammatory bowel disease who on are stable doses of infliximab or adalimumab for at least 3 months who experience a secondary loss of response to the medication based on clinical symptoms. * Presence of at least one objective marker of active disease: active disease based on endoscopy, elevated fecal calprotectin or serologic markers of inflammation (C-reactive protein or sedimentation rate). * Crohn's patients have a Harvey Bradshaw index \>5 * Ulcerative colitis patients have a Ulcerative Colitis Clinical Score \> 5 * Have an undetectable or inadequate trough level of infliximab or adalimumab and detectable ATI or ADA. * Oral corticosteroid therapy is allowed. (prednisone at a stable dose ≤30 mg/day, budesonide at a stable dose ≤9 mg/day, or equivalent steroid) provided that the dose has been stable for the 4 weeks immediately prior to enrollment if corticosteroids have recently been initiated
Exclusion criteria
* Previous noncompliant with medications * \< 18 years of age or \>80 years of age. * Congestive heart failure * Abnormal liver tests alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 2 × the upper limit of normal (ULN) or leucopenia WBC count \<3 × 109/L * Pregnant or planning on becoming pregnant. * Active tuberculosis or hepatitis B infection * Any cancer within the past 5 years. (Exception non-melanomatous skin cancer.) * Receiving any immunomodulator therapy within the past 3 months * Evidence of or treatment for C. difficile infection within 60 days or other intestinal pathogen within 30 days prior to enrollment * Clinically significant extra-intestinal infection (e.g., pneumonia, pyelonephritis) within 30 days of the initial screening visit * Any live vaccinations within 30 days prior to study drug administration except for the influenza vaccine * Any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus \[HIV\] infection, organ transplantation) * Any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise patient safety * Unable to give own informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Eliminate Antibodies: Threshold Levels for ATI is < 3.1and is < 1.7 for ADA. | 4 months | unwanted immunogenicity is an immune response by an organism against a therapeutic antigen. This reaction leads to production of anti-drug antibodies inactivating the therapeutic effects of the treatment. |
| Therapeutic Trough Level for Infliximab is Defined as >3 and as > 5 for Adalimumab. | 4 months | Trough level is the lowest level of drug detected in a subject prior to next dose of medication |
| Ulcerative Colitis Clinical Score UCCS Decrease >3 Points or Remission Score <3 | 4 months | UCCS is the ulcerative colitis clinical score which is based on disease activity. The score is based on bowel movements, blood in stool, overall well being, and global assessment. |
| Change Inflammatory Bowel Disease Questionnaire SIBDQ | 4 months | SIBDQ is the short inflammatory bowel disease questionnaire which is a health-related quality of life tool measuring physical, social, and emotional status. |
| Harvey Bradshaw Index HBI: Decrease >3 Points or Remission Score<5 | 4 months | The Harvey-Bradshaw index (HBI) is a simplified version of the CDAI to foster a systematic collection of clinical data related to Crohn's disease. The index considers five parameters, exclusively clinical; patient well-being, abdominal pain, number of liquid or soft stools, abdominal mass, and complications. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement or Normalization of C-reactive Protein, Sedimentation Rate and Fecal Calprotectin | 4 months | c-reactive protein, sedimentation rate, and fecal calprotectin were collected to monitor the level of inflammation in the subject. Improvement was determined if inflammation level was reduced. |
| Improvement or Normalization of the Simple Endoscopic Score-Crohn's Disease (SES-CD) | 4 months | SESCD is the simple endoscopic score for crohn's disease patients scored during endoscopy. The scoring is based on appearance of ulcers/sizing, % of ulcerative surface, % of affected surface, and if there were any narrowings or strictures found. |
| Improvement or Normalization of Mayo Endoscopy Score for UC Patients | 4 months | Mayo endoscopy score is scoring completed during the endoscopy to evaluate disease activity. Scoring is based on stool frequency, rectal bleeding, mucosal appearance at endoscopy, and physician rating of disease activity |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Immunomodulator Azathioprine, 6 mercaptopurine or methotrexate.
Azathioprine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
6 mercaptopurine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Methotrexate: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine. | 3 |
| Total | 3 |
Baseline characteristics
| Characteristic | Immunomodulator |
|---|---|
| Above-Normal C-Reactive Protein | 2.0 mg/dL |
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants |
| Age, Continuous | 48 years STANDARD_DEVIATION 14 |
| Albumin | 4.37 gm/dL |
| Alkaline Phosphatase | 93.33 units/L |
| ALT | 23.67 units/L |
| Antibodies to Adalimumab concentration | 2.8 units/mL |
| Antibodies to Infliximab concentration | 20.70 units/mL |
| Aspartate Aminotransferase | 21.00 units/L |
| Bilirubin | 0.67 mg/dL |
| Calprotectin | 331.50 mCg/gm |
| Duration of Disease | 16.66666667 years |
| Erythrocyte Sedimentation Rate | 23.67 mm/hr |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Harvey Bradshaw Index (HBI) Score | 4.67 points |
| Hemoglobin | 13.63 gm/dL |
| Platelet Count | 256.00 x 10^3 cells/mm^3 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 3 Participants |
| Region of Enrollment United States | 3 Participants |
| Serum Adalimumab concentration | 2 ug/mL |
| Serum Infliximab concentration | 6.3 ug/mL |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 1 Participants |
| Short Inflammatory Bowel Disease Questionnaire | 46.00 points |
| Simple Endoscopic Score for Crohn's Disease | 6.67 points |
| White Blood Cell Count (WBC) | 6.566666667 x 10^3 cells/mm^3 |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 3 |
| other Total, other adverse events | 0 / 3 |
| serious Total, serious adverse events | 0 / 3 |
Outcome results
Primary
Change Inflammatory Bowel Disease Questionnaire SIBDQ
SIBDQ is the short inflammatory bowel disease questionnaire which is a health-related quality of life tool measuring physical, social, and emotional status.
Time frame: 4 months
Population: Not enough subjects for analysis
Primary
Eliminate Antibodies: Threshold Levels for ATI is < 3.1and is < 1.7 for ADA.
unwanted immunogenicity is an immune response by an organism against a therapeutic antigen. This reaction leads to production of anti-drug antibodies inactivating the therapeutic effects of the treatment.
Time frame: 4 months
Population: Not enough subjects for analysis
Primary
Harvey Bradshaw Index HBI: Decrease >3 Points or Remission Score<5
The Harvey-Bradshaw index (HBI) is a simplified version of the CDAI to foster a systematic collection of clinical data related to Crohn's disease. The index considers five parameters, exclusively clinical; patient well-being, abdominal pain, number of liquid or soft stools, abdominal mass, and complications.
Time frame: 4 months
Population: Not enough subjects for analysis
Primary
Therapeutic Trough Level for Infliximab is Defined as >3 and as > 5 for Adalimumab.
Trough level is the lowest level of drug detected in a subject prior to next dose of medication
Time frame: 4 months
Population: Not enough subjects for analysis
Primary
Ulcerative Colitis Clinical Score UCCS Decrease >3 Points or Remission Score <3
UCCS is the ulcerative colitis clinical score which is based on disease activity. The score is based on bowel movements, blood in stool, overall well being, and global assessment.
Time frame: 4 months
Population: Not enough subjects for analysis
Secondary
Improvement or Normalization of C-reactive Protein, Sedimentation Rate and Fecal Calprotectin
c-reactive protein, sedimentation rate, and fecal calprotectin were collected to monitor the level of inflammation in the subject. Improvement was determined if inflammation level was reduced.
Time frame: 4 months
Population: Not enough subjects for analysis
Secondary
Improvement or Normalization of Mayo Endoscopy Score for UC Patients
Mayo endoscopy score is scoring completed during the endoscopy to evaluate disease activity. Scoring is based on stool frequency, rectal bleeding, mucosal appearance at endoscopy, and physician rating of disease activity
Time frame: 4 months
Population: Not enough subjects for analysis
Secondary
Improvement or Normalization of the Simple Endoscopic Score-Crohn's Disease (SES-CD)
SESCD is the simple endoscopic score for crohn's disease patients scored during endoscopy. The scoring is based on appearance of ulcers/sizing, % of ulcerative surface, % of affected surface, and if there were any narrowings or strictures found.
Time frame: 4 months
Population: Not enough subjects for analysis